Shareholder dissent and derivative threat
Over- and under-responding are both mistakes. Read the rung.
Note
If the clock is running now, call directly.
A letter arrives from a minority shareholder’s counsel. It might request specific information under Art. 697 OR. It might signal intent to petition for a special investigation under Art. 697a OR. It might foreshadow an Art. 706 OR challenge to last month’s general-meeting resolution. Or it might describe in detail a contemplated Art. 754 OR liability action against the directors. These are not the same event. Swiss law organises shareholder remedies as a graduated ladder, and the board’s first — and most common — mistake is to respond as if every rung were the top one. Read the letter for the specific remedy the shareholder is invoking; respond to that remedy’s doctrine; do not escalate by over-response, and do not temporise by under-response.
1. The duties that bear on this
Information rights under Art. 697 OR. Shareholders are entitled to information about the company’s affairs, subject to the business-secret exception. Refusal must be specific, not boilerplate; the enforcement route — court order within one month — is fast and frequently grants the information. An over-refusal produces both the disclosure and adverse framing; an under-refusal may disclose information the company legitimately should have protected.
Special investigation under Art. 697c ff. OR (post-2023). The shareholder moves at the general meeting (Art. 697c) and, on rejection, petitions the court (Art. 697d). The thresholds are now lower — 5% for listed, 10% for non-listed — and the remedy is accessible to more minorities than before. The investigation is commissioned by the court; its report is accessible to all shareholders; its process is itself disruptive.
Challenge of resolutions under Art. 706 OR. Two months from the general meeting. Procedural defects, violation of law or articles, abuse of majority. The two-month window is substantive and strict.
Liability action under Art. 754 OR. Shareholders may bring an action for damage to the company caused by director breach of duty; recovery runs to the company. In bankruptcy, the action passes to the creditors through Art. 260 SchKG cession.
2. The process
- Read the letter carefully. What remedy is being invoked — information, special investigation, Art. 706 challenge, Art. 754 liability? What specific facts are the shareholders pointing at?
- Open a formal file with the general counsel or external counsel. Preserve the letter, the routing, and all responsive communications.
- Triage: is the underlying substantive complaint credible on its face, and — independent of the remedy invoked — does it point at a governance issue the board should be investigating?
- Engage external counsel where the conflict structure requires it (any director personally implicated) or where the threat is material.
- Respond to the specific remedy in the specific form and within the specific timeframe. An Art. 697 information request deserves a calibrated response; a special-investigation threat deserves a substantive posture; an Art. 706 challenge deserves a timely answer to the statement of claim.
- Consider engagement. Not every shareholder dispute goes to litigation. Where the underlying grievance has merit, a calibrated concession — updated disclosure, a governance review, an independent director appointment — may prevent escalation.
- Do not antagonise. Tone is substantively consequential in shareholder disputes; a defensive, dismissive, or lawyerly first response frequently hardens into the litigation posture both sides will occupy for years.
3. Questions to ask counsel and the board
- What specific remedy has the shareholder invoked, and what is its doctrinal framework?
- Is there a structural governance defect the shareholder is pointing at? Have we independently verified the underlying facts?
- Is any sitting director conflicted from the response?
- What information is the shareholder legitimately entitled to under Art. 697, and what are we protecting on business-secret grounds — specifically?
- If this escalates to a special investigation, what would the investigator find?
- If this escalates to an Art. 706 challenge, what is our procedural defence on the resolution in question?
- If this escalates to Art. 754 liability, who is the defendant, what is the quantum, and what is the D&O response?
- What is the shareholder’s underlying objective — information, governance change, compensation, exit?
- Is there a calibrated response that would defuse the matter without either capitulating or antagonising?
- What is our communications posture, and does our response need to be disclosed to other shareholders or — for listed companies — to the market?
4. The record to leave
The inbound letter and every subsequent communication with the shareholder; the board or committee consideration of the response in substantive minutes; any external counsel’s advice and the board’s weighing of it; the specific response sent, in writing; and — if governance or disclosure changes were made in response — the internal record of those changes and their rationale. In the event of escalation, this file is the defence.
5. Failure modes
Boilerplate refusal. The shareholder requests specific information that is genuinely within the Art. 697 scope. The company’s response is a refusal citing general “business-secret” grounds without specification. The court orders production; the refusal becomes the opening frame of the subsequent dispute. The board’s posture — defensive from the outset — shapes every subsequent step.
Over-disclosure to a hostile party. Facing a shareholder who is effectively a competitor or an activist planning an exit, the board over-discloses in an attempt to de-escalate. The information reaches the public domain through shareholder communications with other shareholders or the press; the company’s competitive position is materially harmed.
Missed two-month window. The board assumes a shareholder grumbling about last month’s AGM will eventually either sue or calm down. The Art. 706 two-month window closes; the challenge is filed on day 58; the company’s procedural defence is thin because the board did not treat the window as live.
Cognitive register. Shareholder dissent reliably provokes reactance (Brehm, 1966) — the psychological response to a perceived constraint on one’s autonomy is to push back in the opposite direction — and the board’s instinct is to refuse the requests as a matter of posture rather than to assess them on merits. In-group defence closes the incumbent board’s ranks against the dissenting shareholder, who is cognitively characterised as “a problem” rather than as a signal that something in the governance structure is producing dissent. The escalation trap this creates is familiar from the non-pursuit pattern in ARAG: under psychological pressure, boards make decisions that look reasonable in the moment and indefensible three years later. The discipline of responding to the specific remedy invoked, rather than to the dissent in general, counters both biases at once.